D. Boral Capital Issues Pessimistic Forecast for Carisma Therapeutics (NASDAQ:CARM) Stock Price

Carisma Therapeutics (NASDAQ:CARM) had its price objective reduced by equities researchers at D. Boral Capital from $12.00 to $1.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. D. Boral Capital’s price objective suggests a potential upside of 222.58% from the stock’s previous close.

CARM has been the subject of a number of other research reports. HC Wainwright reaffirmed a “neutral” rating on shares of Carisma Therapeutics in a report on Monday, December 16th. BTIG Research downgraded shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Robert W. Baird cut shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $10.00 to $1.00 in a report on Thursday, December 12th. Baird R W cut Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Evercore ISI reaffirmed an “in-line” rating and set a $0.70 target price (down from $4.00) on shares of Carisma Therapeutics in a report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Carisma Therapeutics currently has a consensus rating of “Hold” and an average price target of $2.74.

Carisma Therapeutics Trading Down 6.1 %

Carisma Therapeutics stock opened at $0.31 on Tuesday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a market cap of $12.94 million, a PE ratio of -0.20 and a beta of 1.55. The stock has a 50-day moving average of $0.44 and a two-hundred day moving average of $0.66. Carisma Therapeutics has a one year low of $0.31 and a one year high of $2.30.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Barclays PLC lifted its stake in Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares during the last quarter. Wexford Capital LP boosted its stake in Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares during the period. Finally, Renaissance Technologies LLC grew its position in Carisma Therapeutics by 11.9% during the 4th quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock worth $97,000 after purchasing an additional 24,600 shares during the last quarter. 44.27% of the stock is owned by hedge funds and other institutional investors.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.